AGS67E

AGS67E is an investigational antibody-drug conjugate (ADC) designed for the treatment of various types of cancer. It is being developed by Agensys, a biotechnology company that focuses on the development of novel therapies for cancer.

Mechanism of Action

AGS67E is composed of a fully human monoclonal antibody that targets the cell surface protein CD37, which is commonly expressed on B-cell malignancies. The antibody is linked to a potent cytotoxic agent, monomethyl auristatin E (MMAE), through a stable linker. Upon binding to CD37 on the surface of cancer cells, AGS67E is internalized, and the linker is cleaved, releasing MMAE into the cell. MMAE disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Clinical Development

AGS67E is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in patients with relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Early-phase clinical trials have shown promising results, with manageable toxicity profiles and evidence of anti-tumor activity.

Potential Indications

AGS67E is being investigated for use in several types of B-cell malignancies, including:

• Non-Hodgkin lymphoma (NHL)
• Chronic lymphocytic leukemia (CLL)
• Diffuse large B-cell lymphoma (DLBCL)
• Mantle cell lymphoma (MCL)

Side Effects

As with other antibody-drug conjugates, AGS67E may cause a range of side effects. Commonly reported adverse events include:

• Neutropenia
• Peripheral neuropathy
• Fatigue
• Nausea
• Diarrhea

See Also

• Antibody-drug conjugate
• Monoclonal antibody
• B-cell
• Non-Hodgkin lymphoma
• Chronic lymphocytic leukemia
• Diffuse large B-cell lymphoma
• Mantle cell lymphoma